SWECHCHHA Pradhan

Ms. SWECHCHHA Pradhan

Arizona State University

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 July 2018 in Nature Methods
Verified
Journal Article
Closed access
PDF file
NYNan Cher Yeo
Nan Cher Yeo
ACAlejandro Chavez
Alejandro Chavez
ALAlissa Lance-Byrne
Alissa Lance-Byrne
YCYingleong Chan
Yingleong Chan
DMDavid Menn
David Menn
GCGeorge Church
George Church

21 February 2022 in Viruses
Verified
Journal Article
Open access
PDF file
SPSWECHCHHA Pradhan
SWECHCHHA Pradhan
Arvind VarsaniArvind Varsani
Arvind Varsani
CLChloe Leff
Chloe Leff
CSCarter J. Swanson
Carter J. Swanson
RHRijal Fajar Hariadi
Rijal Fajar Hariadi
Viral aggregation is a complex and pervasive phenomenon affecting many viral families. An increasing number of studies have indicated that it can modulate critical parameters surrounding viral infections, and yet its role in viral infectivity, pathogenesis, and evolution is just beginning to be appreciated. Aggregation likely promotes viral infection by increasing the cellular multiplicity of infection (MOI), which can help overcome stochastic failures of viral infection and genetic defects and subsequently modulate their fitness, virulence, and host responses. Conversely, aggregation can limit the dispersal of viral particles and hinder the early stages of establishing a successful infection. The cost–benefit of viral aggregation seems to vary not only depending on the viral species and aggregating factors but also on the spatiotemporal context of the viral life cycle. Here, we review the knowns of viral aggregation by focusing on studies with direct observations of viral aggregation and mechanistic studies of the aggregation process. Next, we chart the unknowns and discuss the biological implications of viral aggregation in their infection cycle. We conclude with a perspective on harnessing the therapeutic potential of this phenomenon and highlight several challenging questions that warrant further research for this field to advance.

13 February 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
SPSWECHCHHA Pradhan
SWECHCHHA Pradhan
CSCarter Swanson
Carter Swanson
CLChloe Leff
Chloe Leff
ITIsadonna Tengganu
Isadonna Tengganu
MBMelissa H. Bergeman
Melissa H. Bergeman
RHRijal Fajar Hariadi
Rijal Fajar Hariadi
Antivirals are indispensable tools that can be targeted at viral domains directly or indirectly at cellular domains to obstruct viral infections and reduce pathogenicity. Despite their transformative use in healthcare, antivirals have been clinically approved to treat only 10 of the more than 200 known pathogenic human viruses. Additionally, many virus functions are intimately coupled with host cellular processes, which present challenges in antiviral development due to the limited number of clear targets per virus, necessitating an extensive insight into these molecular processes. Compounding this challenge, many viral pathogens have evolved to evade effective antivirals. We hypothesize that a Viral Attachment Blocking Chimera (VirABloC) composed of a viral binder and a bulky scaffold that sterically blocks interactions between a viral particle and a host cell may be suitable for the development of antivirals agnostic to the extravirion epitope that is being bound. We test this hypothesis by modifying a nanobody that specifically recognizes a non-essential epitope presented on the extra virion surface of Pseudorabies virus strain 486 with a 3-dimensional wireframe DNA origami structure ∼100 nm in diameter. The nanobody switches from having no inhibitory properties (tested up to 50 µM) to 4.2 ± 0.9 nM IC 50 when conjugated with the DNA origami scaffold. Mechanistic studies support that inhibition is mediated by the non-covalent attachment of the DNA origami scaffold to the virus particle, which obstructs the attachment of the viruses onto host cells. These results support the potential of VirABloC as a generalizable approach to developing antivirals.